Phospho-JAK2 (Y221) Antibody

What is the functional significance of JAK2 phosphorylation at tyrosine 221?

Phosphorylation at tyrosine 221 (Y221) plays a crucial activating role in JAK2 signaling. Unlike other phosphorylation sites, Y221 phosphorylation specifically increases ligand-independent JAK2 tyrosine kinase activity, making it a key regulatory site for JAK2 function . This phosphorylation event occurs downstream of the initial activation step (phosphorylation at Y1007/Y1008 in the activation loop) and contributes to signal amplification in JAK2-dependent pathways . Research has demonstrated that inhibition of Y221 phosphorylation, such as through type II JAK inhibitors like CHZ868, can suppress JAK2 activity and downstream JAK-STAT signaling, highlighting its importance in maintaining JAK2 activation .

How does Phospho-JAK2 (Y221) Antibody compare to antibodies targeting other JAK2 phosphorylation sites?

The Phospho-JAK2 (Y221) Antibody specifically recognizes JAK2 when phosphorylated at tyrosine 221, distinguishing it from antibodies targeting other phosphorylation sites such as Y1007/Y1008 (activation loop), Y372/Y373, Y570, or S523 . While antibodies against the activation loop (Y1007/Y1008) detect the initial activation state of JAK2, the Y221 antibody captures a distinct regulatory aspect of JAK2 signaling . This specificity is particularly valuable when investigating the differential regulation of JAK2 under various stimuli or in disease states. Unlike antibodies targeting inhibitory phosphorylation sites (Y570, S523), the Y221 antibody detects an activating modification, making it useful for assessing positive regulation of JAK2 signaling pathways .

What are the validated applications for Phospho-JAK2 (Y221) Antibody?

The Phospho-JAK2 (Y221) Antibody has been validated for several key research applications:

• Western blotting (recommended dilution 1:500 - 1:2000)

• Enzyme-linked immunosorbent assay (ELISA)

While not explicitly stated in all sources, this antibody may also be useful for immunohistochemistry applications given its specificity for the phosphorylated form of JAK2 . The observed molecular weight of phospho-JAK2 detected by this antibody is approximately 125kDa, which is slightly lower than the calculated molecular weight of 131kDa, likely due to post-translational modifications and protein processing .

How does Y221 phosphorylation interact with other JAK2 phosphorylation sites in the regulation of JAK2 activity?

JAK2 regulation involves a complex interplay between multiple phosphorylation sites with distinct functions. Research indicates that Y221 phosphorylation works in concert with Y1007/Y1008 phosphorylation in the activation loop to promote JAK2 activity . These activating phosphorylation events are counterbalanced by inhibitory phosphorylation at sites such as Y570 and S523, which are implicated in negative regulation of JAK2 .

In the context of drug resistance to type I JAK inhibitors, CHZ868 (a type II JAK inhibitor) suppresses both Y1007/Y1008 and Y221 phosphorylation while leaving inhibitory phosphorylation at Y570 and S523 intact . This selective inhibition pattern suggests that Y221 phosphorylation is part of a coordinated activation mechanism that can be targeted therapeutically. The functional relationship between Y221 and other phosphorylation sites appears hierarchical - with activation loop phosphorylation likely preceding Y221 phosphorylation in most signaling contexts, though both are necessary for maximal JAK2 activity .

What is the role of Phospho-JAK2 (Y221) in JAK2 heterodimer formation and transphosphorylation?

JAK2 heterodimer formation with JAK1 or TYK2 has been implicated in persistent JAK-STAT signaling and resistance to type I JAK inhibitors . Research on CHZ868, a type II JAK2 inhibitor, demonstrated that it renders activating phospho-sites of JAK2, including Y221, less accessible for transphosphorylation in heterodimers .

The mechanism appears to involve:

• Type II inhibition restricting accessibility of JAK2 for transphosphorylation by stabilizing JAK2 in an inactive conformation

• Reduced JAK1-mediated phosphorylation of both Y1007/Y1008 and Y221 in JAK2

• Maintenance of inhibitory phosphorylation at Y570 and S523

This selective impact on heterodimer-mediated phosphorylation results in suppression of JAK-STAT signaling even in cells resistant to type I JAK inhibitors . Researchers studying JAK2 activation mechanisms should consider assessing Y221 phosphorylation alongside Y1007/Y1008 to gain comprehensive insights into heterodimer-dependent signaling processes.

How does Y221 phosphorylation differ from Y372 phosphorylation in regulating JAK2 function?

Y221 and Y372 represent two distinct regulatory phosphorylation sites in JAK2 with differing impacts on kinase activation:

While Y221 phosphorylation plays a primarily activating role, Y372 appears to have differential effects depending on the stimulus type - critical for interferon-γ and EGF-mediated JAK2 activation but dispensable for hydrogen peroxide-mediated activation . This suggests these phosphorylation sites integrate different upstream signals to fine-tune JAK2 responses in a context-dependent manner .

What are the critical controls when using Phospho-JAK2 (Y221) Antibody in signaling studies?

When investigating JAK2 signaling using the Phospho-JAK2 (Y221) Antibody, researchers should implement several critical controls:

• Total JAK2 detection: Always include antibodies detecting total JAK2 protein to normalize phosphorylation levels and account for variations in total protein expression .

• Activation state verification: Include detection of activation loop phosphorylation (Y1007/Y1008) to correlate with Y221 phosphorylation status .

• Downstream signaling assessment: Measure STAT phosphorylation (particularly STAT1, STAT3, or STAT5) to confirm functional consequences of JAK2 activation .

• Dephosphorylation control: Treatment with phosphatase inhibitors is essential during sample preparation to preserve phosphorylation status .

• Stimulation controls: Include both positive controls (cytokine or growth factor stimulation) and negative controls (JAK inhibitor treatment) to validate antibody specificity .

• Cross-reactivity assessment: Verify specificity by comparing detection in JAK2-null cells versus JAK2-expressing cells to exclude cross-reactivity with other JAK family members .

These controls ensure accurate interpretation of phospho-JAK2 (Y221) detection and its relationship to JAK2 activation status in experimental systems.

How should phospho-JAK2 (Y221) detection be optimized in Western blotting experiments?

Optimizing detection of phospho-JAK2 (Y221) in Western blotting requires careful attention to several methodological factors:

• Sample preparation: Lyse cells in buffer containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) to preserve phosphorylation status .

• Protein loading: The recommended protein loading is 20-40μg of total protein per lane to achieve optimal signal-to-noise ratio.

• Membrane blocking: Use 5% BSA in TBST rather than milk-based blocking buffers, as milk contains phosphatases that may reduce phospho-epitope detection .

• Antibody dilution: Start with the recommended dilution (1:500 - 1:2000) and optimize based on signal strength and background .

• Positive control: Include lysates from K562 cells, which have been validated as a positive sample for phospho-JAK2 (Y221) detection .

• Visualization method: Enhanced chemiluminescence (ECL) provides sufficient sensitivity, but consider fluorescent secondary antibodies for quantitative analysis.

• Stripping considerations: If performing multiple detections on the same membrane, detect phospho-JAK2 first before stripping and reprobing for total JAK2, as phospho-epitopes are more sensitive to loss during stripping procedures .

What approaches can be used to study the functional significance of Y221 phosphorylation in JAK2 signaling?

Several complementary approaches can be employed to elucidate the functional significance of Y221 phosphorylation:

• Site-directed mutagenesis: Generate Y221F mutants to prevent phosphorylation at this site, similar to approaches used for studying Y372 function . Compare kinase activity, downstream signaling, and biological outcomes between wild-type and mutant JAK2.

• Phosphomimetic mutation: Create Y221E or Y221D mutants to mimic constitutive phosphorylation and assess gain-of-function effects.

• Type II JAK inhibitors: Utilize inhibitors like CHZ868 that differentially affect Y221 phosphorylation to probe its role in JAK2 signaling and drug resistance mechanisms .

• Heterodimer analysis: Employ co-immunoprecipitation and proximity ligation assays to investigate how Y221 phosphorylation affects JAK2 heterodimer formation with JAK1/TYK2 .

• JAK2 V617F contexts: Compare Y221 phosphorylation in wild-type versus V617F mutant JAK2 to understand its role in pathological JAK2 activation in myeloproliferative disorders .

• SOCS protein interactions: Investigate how Y221 phosphorylation influences binding and regulation by SOCS proteins, particularly SOCS3, which is known to interact with JAK2 .

• Functional readouts: Assess proliferation, differentiation, and cytokine responsiveness in cellular models with manipulated Y221 phosphorylation status to connect molecular changes to biological outcomes.

How is phospho-JAK2 (Y221) status altered in myeloproliferative disorders with JAK2 V617F mutation?

The JAK2 V617F mutation, found in up to 90% of patients with polycythemia vera and in significant proportions of patients with essential thrombocythemia and idiopathic myelofibrosis, likely influences Y221 phosphorylation patterns . While the search results don't directly address Y221 phosphorylation in JAK2 V617F contexts, several insights can be inferred:

• JAK2 V617F exhibits constitutive activation due to altered JH2 domain function, which normally inhibits the JH1 kinase domain .

• This constitutive activation likely leads to increased phosphorylation at multiple sites, including Y221, contributing to ligand-independent signaling.

• JAK2 V617F overcomes normal SOCS regulation, with evidence showing that SOCS3 cannot inhibit the mutant kinase and may even potentiate its activity .

• The hyperphosphorylation observed in JAK2 V617F likely extends to Y221, potentially enhancing its activating effects on JAK2 signaling.

Research investigating differential phosphorylation patterns between wild-type and V617F JAK2 would provide valuable insights into how Y221 phosphorylation contributes to pathological JAK2 activation in myeloproliferative disorders .

What is the potential of targeting JAK2 Y221 phosphorylation in therapeutic strategies?

Targeting JAK2 Y221 phosphorylation represents a promising therapeutic approach based on several lines of evidence:

• Type II JAK inhibitors: Compounds like CHZ868 that inhibit Y221 phosphorylation have shown efficacy in overcoming resistance to type I JAK inhibitors, suggesting Y221 phosphorylation may be a key mechanism in drug resistance .

• Heterodimer-mediated activation: Y221 phosphorylation appears involved in heterodimer-mediated transactivation of JAK2, which drives persistent JAK-STAT signaling in resistant cells .

• Ligand-independent activity: Since Y221 phosphorylation increases ligand-independent JAK2 activity, targeting this site may specifically reduce pathological JAK2 activation while preserving normal cytokine-induced signaling .

• Differential regulation: The distinct regulatory mechanism of Y221 compared to other phosphorylation sites offers potential for selective therapeutic targeting .

• Disease context: In myeloproliferative disorders with JAK2 V617F mutation, targeting Y221 phosphorylation might provide an alternative approach to inhibiting the pathologically activated kinase .

Future therapeutic development may benefit from compounds specifically designed to prevent Y221 phosphorylation or to disrupt protein interactions dependent on this phosphorylation event, potentially offering more selective JAK2 inhibition with reduced side effects compared to current JAK inhibitors .

How can researchers differentiate between Y221 and other tyrosine phosphorylation sites in JAK2?

Differentiating between various phosphorylation sites in JAK2 requires careful methodological approaches:

• Phospho-specific antibodies: Use highly specific antibodies targeting individual phosphorylation sites, such as the Phospho-JAK2 (Y221) Antibody .

• Mass spectrometry: For comprehensive phosphorylation analysis, liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify and quantify multiple phosphorylation sites simultaneously, as was used to identify novel sites Y372 and Y373 .

• Mutational analysis: Generate site-specific tyrosine-to-phenylalanine mutants (Y→F) to confirm antibody specificity and assess functional consequences of specific phosphorylation events .

• Phosphatase treatments: Differential sensitivity to specific phosphatases can help distinguish between phosphorylation sites.

• Time-course experiments: Different phosphorylation sites may have distinct temporal dynamics following stimulation, allowing temporal resolution of phosphorylation events .

• Inhibitor specificity: Type I versus type II JAK inhibitors differentially affect certain phosphorylation sites (e.g., CHZ868 inhibits Y221 phosphorylation while leaving Y570 and S523 intact), which can be leveraged for site discrimination .

Using a combination of these approaches provides the most robust differentiation between Y221 and other phosphorylation sites in JAK2.

What are the recommended experimental conditions for studying Y221 phosphorylation dynamics?

To optimally study Y221 phosphorylation dynamics, researchers should consider these experimental conditions:

• Cell types: Use cells with robust JAK2 expression, such as K562 cells (validated as a positive control), or cell lines expressing hematopoietic cytokine receptors that signal through JAK2 .

• Stimulation protocols:

  • For rapid induction: Cytokines like erythropoietin (EPO), interferon-gamma (IFNγ), or growth factors like EGF at 10-100 ng/mL for 5-30 minutes .

  • For sustained phosphorylation: Lower concentrations (1-10 ng/mL) for longer periods (1-24 hours).

• Inhibitor studies:

  • Type I JAK inhibitors (ruxolitinib, CYT387, BMS911543): 0.1-1 μM

  • Type II JAK inhibitors (CHZ868): 0.1-1 μM

  • Include washout studies to assess phosphorylation recovery dynamics

• Lysis conditions: Use RIPA or NP-40 buffer supplemented with phosphatase inhibitors (10 mM sodium orthovanadate, 50 mM sodium fluoride, 10 mM β-glycerophosphate) and protease inhibitors .

• Temperature considerations: Perform cell stimulation and lysis at physiological temperature (37°C) to maintain normal kinase activity, but conduct subsequent steps at 4°C to minimize post-lysis dephosphorylation.

• Time points: For kinetic studies, collect samples at 0, 5, 15, 30, 60, 120, and 240 minutes post-stimulation to capture both rapid and sustained phosphorylation changes .

• Controls: Include both positive controls (cytokine stimulation) and negative controls (JAK inhibitor pre-treatment) in each experiment to validate phosphorylation specificity.

These conditions should provide robust and reproducible assessment of Y221 phosphorylation dynamics across various experimental contexts.